Q-omics provides the consensus-scored LRRC56 profile across patient tissues and cancer cell-line models. LRRC56 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LRRC56 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, LRRC56 RNA expression shows 18,881 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, KICH, and ACC as cancer lineages where LRRC56 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC56 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC56 survival associations across molecular data types. LRRC56 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC56 RNA expression–survival associations across cancer types. High LRRC56 expression shows unfavorable associations in ACC and COAD, but favorable associations in HNSC, UVM, BRCA and MESO. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LRRC56 RNA expression.
This table summarizes LRRC56 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC56. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC56 shows lower tumor expression in KICH and LUSC and higher tumor expression in STAD, LIHC, BRCA and CHOL. The KICH box plot shows higher LRRC56 RNA expression in normal versus tumor tissue (log2 FC = −2.017, t-test p < 0.001).
This table shows molecular features associated with LRRC56 in patient tissues and cancer cell lines. In patient samples, LRRC56 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC56 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
